Gene expression profiles reveal homeostatic dynamics during interferon-β therapy in multiple sclerosis

Autoimmunity

Volumn 40, Issue 1, 2007, Pages 16-22

  Annibali, Viviana ^a   Di Giovanni, Simone ^a   Cannoni, Stefania ^a   Giugni, Elisabetta ^b   Bomprezzi, Roberto ^a,c   Mattei, Carlo ^a   Elkahloun, Abdel ^c   Coccia, Eliana Marina ^d   Alfò, Marco ^e   Orzi, Francesco ^a   Ristori, Giovanni ^a   Salvetti, Marco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

cDNA microarrays; Gene expression; Interferon ; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; FILAMIN; INTERLEUKIN 10; INTERLEUKIN 16; RAB7 PROTEIN;

ADULT; ANTIGEN PRESENTATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG MECHANISM; DRUG RESPONSE; FEMALE; GENE EXPRESSION PROFILING; HOMEOSTASIS; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; UNINDEXED SEQUENCE; UPREGULATION;

ADULT; CONTRACTILE PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; INTERFERON-BETA; INTERLEUKIN-10; INTERLEUKIN-16; MAGNETIC RESONANCE IMAGING; MALE; MICROFILAMENT PROTEINS; MULTIPLE SCLEROSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RAB GTP-BINDING PROTEINS;

EID: 33847377610     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930601135241     Document Type: Article

References (12)

1. Goodin, DS,.Frohman, EM and Garmany Jr., GP (2002) Disease modifying therapies in multiple sclerosis: Report of the Therapeutics And Technology Assessment Subcommittee of The American Academy Of Neurology and the MS Council For Clinical Practice Guidelines. Neurology, 58, pp. 169-178.
2. Koike, F.,.Satoh, J. and Miyake, S. (2003) Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis. J Neuroimmunol, 139, pp. 109-118.
3. Weinstock-Guttman, B.,.Badgett, D. and Patrick, K. (2003) Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol, 171, pp. 2694-2702.
4. Chen, E. and Hasseman, JP (2002) Within the fold: Assessing differential expression measures and reproducibility in microarray assays. Genome Biol, 3
5. Sturzebecher, S.,.Wandinger, KP and Rosenwald, A. (2003) Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain, 126, pp. 1419-1429.
6. Byskosh, PV and Reder, AT (1996) Interferon beta-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Mult Scler, 1, pp. 262-269.
7. Byrnes, AA,.McArthur, JC and Karp, CL (2002) Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann Neurol, 51, pp. 165-174.
8. Bertram, EM,.Hawley, RG and Watts, TH (2002) Overexpression of rab7 enhances the kinetics of antigen processing and presentation with MHC class II molecules in B cells. Int Immunol, 14, pp. 309-318.
9. Skundric, DS,.Dai, R. and Zakarian, VL (2005) Anti-IL-16 therapy reduces CD4+ T-cell infiltration and improves paralysis and histopathology of relapsing EAE. J Neurosci Res, 79, pp. 680-693.
10. Wandinger, KP,.Sturzebecher, CS and Bielekova, B. (2001) Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol, 50, pp. 349-357.
11. Fainardi, E.,.Rizzo, R. and Melchiorri, L. (2004) Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy. J Neuroimmunol, 148, pp. 206-211.
12. Negro, F.,.Baldi, M. and Mondardini, A. (1994) Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a. Gastroenterology, 107, pp. 479-485.